Comparison of cefixime and the combination of cefixime and clindamycin in the treatment of patients with acute and chronic sinusitis

Comparison of Cefixime and Cefixime and Clindamycin Combination with Cefixime in the Treatment of Acute and Chronic Sinusitis patients in Imam Khomeini Hospital of Ahwaz

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201112049371N1

Enrollment

120

Registered

2020-12-21

Start date

2020-06-21

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Acute sinusitis. Condition 2: Chronic sinusitis. Acute sinusitis Chronic sinusitis

Interventions

Intervention 1: Intervention group: includes patients with acute sinusitis who receive cefixime tablets (Kowsar company) 400 mg daily and clindamycin capsules (Saha Daroo company) 300 mg three times a

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Initial positive opinion by the ENT specialist on CT scan of the patient's sinuses Patient consent to enter the study

Exclusion criteria

Exclusion criteria: Hypersensitivity to the antibiotic Cefixime Hypersensitivity to the antibiotic clindamycin Recent use of other antibiotics Patients with cystic fibrosis Immune Deficiency Patients

Design outcomes

Primary

Measure	Time frame
Headache. Timepoint: At the beginning of the study and 21 days after the study. Method of measurement: No effect (1 point), partial effect (2 points), partial effect (3 points) or full effect (4 points).;Nasal discharge. Timepoint: At the beginning of the study and 21 days after the study. Method of measurement: No effect (1 point), partial effect (2 points), partial effect (3 points) or full effect (4 points).;Cough. Timepoint: At the beginning of the study and 21 days after the study. Method of measurement: No effect (1 point), partial effect (2 points), partial effect (3 points) or full effect (4 points).;Nasal obstruction. Timepoint: At the beginning of the study and 21 days after the study. Method of measurement: No effect (1 point), partial effect (2 points), partial effect (3 points) or full effect (4 points).;Feeling full in the face. Timepoint: At the beginning of the study and 21 days after the study. Method of measurement: No effect (1 point), partial effect (2 points), partial effect (3 points) or full effect (4 points).;Discharge from the back of the throat. Timepoint: At the beginning of the study and 21 days after the study. Method of measurement: No effect (1 point), partial effect (2 points), partial effect (3 points) or full effect (4 points).	—

Measure

Time frame

Headache. Timepoint: At the beginning of the study and 21 days after the study. Method of measurement: No effect (1 point), partial effect (2 points), partial effect (3 points) or full effect (4 points).;Nasal discharge. Timepoint: At the beginning of the study and 21 days after the study. Method of measurement: No effect (1 point), partial effect (2 points), partial effect (3 points) or full effect (4 points).;Cough. Timepoint: At the beginning of the study and 21 days after the study. Method of measurement: No effect (1 point), partial effect (2 points), partial effect (3 points) or full effect (4 points).;Nasal obstruction. Timepoint: At the beginning of the study and 21 days after the study. Method of measurement: No effect (1 point), partial effect (2 points), partial effect (3 points) or full effect (4 points).;Feeling full in the face. Timepoint: At the beginning of the study and 21 days after the study. Method of measurement: No effect (1 point), partial effect (2 points), partial effect (3 points) or full effect (4 points).;Discharge from the back of the throat. Timepoint: At the beginning of the study and 21 days after the study. Method of measurement: No effect (1 point), partial effect (2 points), partial effect (3 points) or full effect (4 points).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Azam Fazlipour

Ahvaz University of Medical Sciences

info@ajums.ac.ir+98 61 3311 0000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026